1.Clinical Research on Correlation between SOD and TXB_2/6-k-PGF_(l?) in Stroke Patients
Chinese Journal of Information on Traditional Chinese Medicine 2006;0(11):-
Objective To research the correlation between SOD and TXB2/6-k-PGF1? and relationship with TCM syndrome in stroke patients. Methods A contrast test on blood SOD and plasma TXB2 and 6-k-PGF1? was given separately to two groups, one group was 74 cases with stroke and the control group was 36 cases in health. Results Content of b1ood SOD in stroke group reduced remarkably compared with the health group (P
4.Application of circulating tumor cells detection in non-small cell lung cancer
Hao LI ; Sheng LI ; Baijiang ZHANG
Journal of International Oncology 2015;(4):298-300
Circulating tumor cells(CTCs)are essential for establishing metastasis and recurrence in non-small cell lung cancer(NSCLC). With the development of detection technique,results from recent studies suggest that CTC level could be a supplement for TNM staging system and a prediction marker of prognosis and therapeutic efficacy,and even could be applied for risk assessment of early NSCLC. Furthermore,as a non-invasiveliquid biopsy,detection of CTC can reflect the molecular biology and genetics characteristics of the primary tumor,and subsequently assist in selecting an optimal individualized treatment.
5.Research progress of mesenchymal stem cells attenuating acute respiratory distress syndrome by regulating the balance of M1/M2 macrophage polarization
Li ZHENG ; Sheng WANG ; Hao YANG ; Xin LYU
Chinese Critical Care Medicine 2021;33(4):509-512
Acute respiratory distress syndrome (ARDS) is a common clinical critical disease, characterized by progressive respiratory distress, intractable hypoxemia, respiratory failure and so on, with high mortality rate and lack of effective prevention and treatment strategies. In recent years, mesenchymal stem cell (MSC) can be used in the treatment of acute lung injury (ALI), which cannot only replace the damaged lung epithelial cells, but also promote tissue repair and alleviate ARDS by secreting anti-inflammatory and anti-fibrosis factors. This review focuses on the related mechanisms and signal pathways of MSC and its paracrine factors in the treatment of ARDS by regulating the balance of macrophage polarization.
6.No postoperative survival benefit in concurrent chemoradiation treated patients with low-risk early-stage cervical squamous cell carcinoma
Hao YU ; Linlin ZHANG ; Xuelian DU ; Xiugui SHENG
Chinese Journal of Clinical Oncology 2014;46(4):242-245
Objective:The benefits of postoperative adjuvant therapy method for low-risk early-stage cervical squamous cell carcinoma were investigated. Methods:A total of 133 patients with low-risk early-stage cervical squamous cell carcinoma were treated at Shandong Cancer Hospital&Institute from February 2008 to March 2012. All patients received adjuvant therapy:42 were treated with pelvic ra-diotherapy (RT), 47 were treated with adjuvant chemotherapy (CT)+intracavitary radiotherapy (ICRT), and 44 were treated with concurrent chemoradiation (CCRT). Disease-free survival (DFS) and complications of the therapy were evaluated. Results:No significant differences in DFS were observed in the patients treated with RT, CT+ICRT, and CCRT (P>0.05), and the three-year DFS rates were 94.0%, 93.4%, and 97.6%, respectively. The frequencies of grade III to IV acute toxicities were significantly higher in patients treated with CCRT (34.1%) than in those treated with RT (9.5%) or CT+ICRT (16.7%) (P<0.05). No statistically significant difference was observed between the RT group and the CT+ICRT group (P>0.05). Grade I to II late toxicity was significantly more frequent in the CCRT (25%) and RT (19.0%) groups compared with the CT+ICRT group (4.3%) (P>0.05), but no statistically significant differences were observed between the CCRT and the RT groups (P>0.05). Conclusion:CT+ICRT or RT has a three-year DFS rate equivalent to CCRT but with fewer therapy com-plications for low-risk early-stage cervical squamous cell carcinoma.
7.Therapeutic effect of percutaneous vertebroplasty and kyphoplasty on treatment of osteoporotic vertebral compression fracture
Chunyang MENG ; Qingwei LI ; Zhenming HU ; Jie HAO ; Zunqi SHENG
International Journal of Surgery 2011;38(4):248-252
Objective To observe the clinical efficacy of percutaneous vertebroplasty (PVP) with percutaneous kyphoplasty (PKP) in the treatment of osteoporotic vertebral compression fracture(OVCF) by systematic review. Methods From September 2005 to March 2009,46 cases of fresh OVCF were treated. Patients were divided into 2 groups (A, B), according to Jikei grade, Genant semiquantitative method, injury vertebra number. Twenty-five cases(group A)were treated by PVP,8 males and 17 females with the age of 52 - 78 years (average 69). Vertebra segment of fracture was within T6 - L5 (14 in case thoracical vertebrae and 11 lumbar vertebrae). Twenty-one cases(group B)were treated by PKP,There were 6 males and 15 females with the age of 54 - 82 years (average 71). Vertebra segment of fracture was within T6 - L4 (12 in case thoracical vertebrae and 9 lumbar vertebrae). The clinical efficacy, incidence rate of complication, the anterior height of vertebrae body,visual analogue pain scale(VAS) ,ease of pain were measured preoperatively and at 6 weeks, 3 and 6 months and 1 year postoperatively between the two groups. Results All the patients were followed up for 12 -45 months with an average of 23.5 months. The average recovery of anterior height of vertebrae body was respectively(85.95 ± 4.31) % in group A and (93.64 ± 3.35) % in group B,which statistically difference in vertebral height between two groups (P < 0.05). No statistical significant difference was seen in VAS, analgesic durg (AID) and ease of pain complication between two groups (P >0. 05). Statistical significant difference was noted in pre-postoperatively between intra-two groups (P <0. 05). Conclusions PVP and PKP can quickly relieve pain and enhance vertebral stability in treating thoracolumbar OVCF according to evaluation parameter, and have the similar therapeutic efficacy in treatment of OVCF with minimal invasion. However, PKP is superior in the recovery of vertebral height.
8.Endovascular repair for type B aortic dissection
Xiaohu GE ; Qingbo FANG ; Sheng GUAN ; Limu SAI ; Hao REN
Chinese Journal of General Surgery 2011;26(11):907-909
Objective To evaluate thoracic endovascular aortic repair for type B aortic dissection.Methods Chnical data were reviewed on 126 cases with type B aortic dissection undergoing endovascular aortic repair in our hospital from January 2006 to April 2011.There were 86 male patients and 40 female patients,age from 32 to 82 years.The stent- grafts were introduced via femoral arteriotomy.Stent-grafts were implanted to blockade tears of aortic dissection under the guidance of DSA.Postoperatively patients were followed-up by angiography and imiging for endoleak,stent migration,and fracture of stent-graft.Results In all cases,the aortic dissection tears were closed,true lumens were opened,and organ function was restored.There were not complications such as internal hemorrhage due to trauma or stent displacement on CTA from 3 to 63 months after endovascular therapy.Procedure was successful in all 126 cases,157 stents were released,2 cases died in the perioperative period,1 case died during the followed-up.A breach was found at the end of the stent in 12 cases,endovascular aortic repair redone successfully with a retrograde type A dissection found during follow-up.Conclusions Endovascular aortic repair is safe and effective for patients with Stanford type B aortic dissection with a favorable outcomes.
9.Evaluation of the function and synchronization of left atrial in chronic heart failure patients by real-time three-dimensional echocardiography
Sheng CAO ; Ruiqiang GUO ; Jinling CHEN ; Lidan HAO ; Juan HE
Chinese Journal of Ultrasonography 2012;21(2):116-120
Objective To evaluate the function and synchronization of left atrial in patients with chronic heart failure(CHF) by real-time three dimensional echocardiography (RT-3DE).MethodsThirty healthy controls and thirty-two patients with CHF were studied.The CHF were divided into group CHF1 with the normal of left ventricular filling pressure and group CHF2 with the elevated of that.From the volume-time curve of RT-3DE workstation,the maximum volume (LAVmax),the minimum volume (LAVmin),the volume before contraction (LAVp) of left atrial were acquired.Accordingly,the total,passive and active ejection fraction could be calculated.The synchronization parameters derived from RT3DE were the dispersion and maximum difference of time to minimum volume for left atrial segments (Tmsv- 16-SD,Tmsv 12-SD,Tmsv-6-SD,Tmsv- 16-Dif,Tmsv 12-Dif,Tmsv-6 Dif).The index of volume and time were corrected by the body surface area and interval of R-R,respectively.The correlation were analysed in them.Results ① All the index of volume before and after correction were gradually increasing from control to CHF2 group,but the LATEF,LAPEF and LAAEF were just the reverse,with all parameters had significant difference among total groups( P <0.01 ).②The synchronization parameters were significantly higher from control to CHF2 group( P <0.01 ).Comparing between two groups,no significant difference of the synchronization parameters were found between CHF1 group and CHF2 group ( P > 0.05),except Tmsv-16-SD% and Tmsv-16-Dif% ( P <0.01 ).③The Tmsv-16-SD% and Tmsv-16-Dif% had a positive correlation with the index of volume and a negative correlation with the ejection fraction.The most significantly correlation parameters was LAVmaxI,with r =0.75 and P <0.01.ConclusionsThe function of left atrium are reduced in patients of CHF,there are dyssynchronization.The higher of the filling pressure of left ventricle,the lager of the dyssynchronization of left atrium.RT-3DE may paly important roles in the evaluation of function and synchronization of left atrium.
10.Clinicopathologic characteristics and prognostic analysis of luminal B breast cancer patients with diabetes
Bei SUN ; Guofang HOU ; Xiaobei ZHANG ; Xiaomeng HAO ; Sheng ZHANG
Chinese Journal of Clinical Oncology 2013;(17):1042-1046
Objective:To investigate the clinical, pathological, and prognostic characteristics of luminal B breast cancer patients with diabetes. Methods:A total of 479 luminal B breast cancer patients with diabetes and 3 392 luminal B breast cancer patients without diabetes who were treated between January 2002 and December 2006 were enrolled in this study. The luminal B breast cancer patients were further divided into the luminal B (high ki67) and luminal B (Her-2/neu+) subgroups. Each subgroup was further grouped into metformin-treated, non-metformin-treated, and non-diabetic groups. The indicators included cancer-specific mortality, clinical, pathological stage, lymph node status, chemotherapy, and endocrine therapy. The survival analysis of each group was performed using the Kaplan-Meier method, and the significance was determined using the logrank test. Cox proportional hazard model was used to examine the correlation between each factor and the prognosis. Results:The Kaplan-Meier analysis results revealed that the breast cancer mortality rates in the metformin-treated, non-metformin-treated, and non-diabetic groups were significantly different in both luminal B (high ki67) and luminal B (Her-2/neu+) subgroups (logrank test:P<0.001, P=0.035), and the respective five-year survival rates were 93.5%, 81%, and 89%for the luminal B (high ki67) subgroup and 84%, 77%, and 83%for the luminal B (Her-2/neu+) subgroup. The Cox multifactorial regression analysis results showed that compared with the metformin-treated group, the non-metformin-treated group was associated with a significantly increased risk of mortality (P<0.001, P=0.044) in the two subgroups. Meanwhile, the non-diabetic group was associated with an increased risk of mortality (P=0.038) in the luminal B (high ki67) subgroup only. The percentage of elderly (P<0.001), menopausal (P<0.001), obese (P<0.001), and patients with cardio-cerebrovascular complications (P<0.001) tended to be higher in the metformin-treated and non-metformin-treated groups than in the diabetic group. Moreover, the metformin-and non-metformin-treated groups in the luminal B (high ki67) subgroup were associated with high percentages of T3/4 pathological stage (P<0.001), lymph node metastasis (P=0.001). The non-metformin-treated group was associated with a lower percentage of invasive ductal carcinoma (P=0.001) compared with the other two groups. Conclusion:The non-metformin-treated group resulted in worse clinical outcomes in both subgroups compared with the metformin-treated group. Meanwhile, the non-diabetic group resulted in the worst prognosis among the three groups in the luminal B (high ki67) subgroup. These findings suggest that the choice of different anti-diabetic drugs may influence the prognosis of luminal B breast cancer patients with diabetes.